Applications of LC-MS in PET radioligand development and metabolic elucidation

Current Drug Metabolism

Volumn 11, Issue 6, 2010, Pages 483-493

  Ma, Ying ^a   Kiesewetter, Dale O ^a   Lang, Lixin ^a   Gu, Dongyu ^a   Chen, Xiaoyuan ^a  

^a NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING   (United States)

Author keywords

LC MS MS; Metabolite; Positron emission tomography (PET); Radiopharmaceutical

Indexed keywords

(1,4,8,11 TETRAAZACYCLOTETRADECANE 1,4,8,11 TETRAACETIC ACID) CU 64; (4,11 BIS(CARBOXYMETHYL) 1,4,8,1 TETRAAZABICYCLO[6.6.2]HEXADCANE) CU 64; 1 (2 METHOXYPHENYL) 4 [2 (2 PYRIDYL)ETHYL]PIPERAZINE; 3 (3 (3 FLUOROPROPYL)THIO) 1,2,5 THIADIAZOL 4 YL 1,2,5,6 TETRAHYDRO 1 METHYLPYRIDINE F 18; 3 (3 (3 FLUOROPROPYL)THIO) 1,2,5 THIADIAZOL 4 YL 1,2,5,6 TETRAHYDRO 1 METHYLPYRIDINE[19-23]; BPAC BR 76; CYCLOHEXANECARBOXYLIC ACID C 11; DRUG METABOLITE; FLUORINE 18; IPAC I 124; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; MUSCARINIC RECEPTOR; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; N [2 [4 (2 METHOXYPHENYL)PIPERAZINYL]ETHYL] N (PYRIDIN 2Y L)FLUOROCYCLOHEXANE CARBOXAMIDE F 18; PACLITAXEL; PACLITAXEL F 18; RADIOLIGAND; RADIOPHARMACEUTICAL AGENT; SEROTONIN RECEPTOR; UNCLASSIFIED DRUG; XANOMELINE F 18;

CHEMICAL STRUCTURE; CHROMATOGRAPHY; HUMAN; IN VITRO STUDY; LIQUID CHROMATOGRAPHY; LIVER CELL; MASS SPECTROMETRY; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; QUANTITATIVE ANALYSIS; REVIEW; SOLID TUMOR;

ANIMALS; CHROMATOGRAPHY, LIQUID; DRUG DISCOVERY; HUMANS; MASS SPECTROMETRY; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS;

EID: 77954165782     PISSN: 13892002     EISSN: None     Source Type: Journal    
DOI: 10.2174/138920010791636167     Document Type: Review

References (51)

1. Ter-Pogossian, M. M.; Phelps, M. E.; Hoffman, E. J.; Mullani, N. A. A positron-emission transaxial tomograph for nuclear imaging (PETT). Radiology, 1975, 114(1), 89-98.
2. Phelps, M. E.; Hoffman, E. J.; Mullani, N. A.; Ter-Pogossian, M. M. Application of annihilation coincidence detection to transaxial reconstruction tomography. J. Nucl. Med., 1975, 16(3), 210-24.
3. Fowler, J. S.; Ido, T. Initial and subsequent approach for the synthesis of 18FDG. Semin. Nucl. Med., 2002, 32(1), 6-12.
4. Giron, M. C.; Portolan, S.; Bin, A.; Mazzi, U.; Cutler, C. S. Cytochrome P450 and radiopharmaceutical metabolism. Q. J. Nucl. Med. Mol. Imaging, 2008, 52(3), 254-66.
5. Ma, Y.; Kiesewetter, D.; Lang, L.; Eckelman, W. C. Application of LC-MS to the analysis of new radiopharmaceuticals. Mol. Imaging Biol., 2003, 5(6), 397-403. (Pubitemid 37489830)
6. Ma, Y.; Lang, L.; Kiesewetter, D.; Jagoda, E.; Eckelman, W. C. Species differences in metabolites of PET ligands: serotonergic 5-HT1A receptor antagonists 3-trans-FCWAY and 3-cis-FCWAY. Nucl. Med. Biol., 2006, 33(8), 1013-9.
7. Chu, I.; Nomeir, A. A. Utility of mass spectrometry for in-vitro ADME assays. Curr. Drug Metab., 2006, 7(5), 467-77.
8. Korfmacher, W. A. Principles and applications of LC-MS in new drug discovery. Drug Discov. Today, 2005, 10(20), 1357-67.
9. Lang, L.; Jagoda, E.; Ma, Y.; Sassaman, M. B.; Eckelman, W. C. Synthesis and in vivo biodistribution of F-18 labeled 3-cis-, 3-trans-, 4-cis-, and 4-trans-fluorocyclohexane derivatives of WAY 100635. Bioorg. Med. Chem., 2006, 14(11), 3737-48.
10. Lang, L.; Jagoda, E.; Schmall, B.; Sassaman, M.; Ma, Y.; Eckelman, W. C. Fluoro analogs of WAY-100635 with varying pharmacokinetics properties. Nucl. Med. Biol., 2000, 27(5), 457-62.
11. Chay, S. H.; Pohland, R. C. Comparison of quantitative wholebody autoradiographic and tissue dissection techniques in the evaluation of the tissue distribution of [14C]daptomycin in rats. J. Pharm. Sci., 1994, 83(9), 1294-9.
12. Yanes, O.; Woo, H. K.; Northen, T. R.; Oppenheimer, S. R.; Shriver, L.; Apon, J.; Estrada, M. N.; Potchoiba, M. J.; Steenwyk, R.; Manchester, M.; Siuzdak, G. Nanostructure initiator mass spectrometry: tissue imaging and direct biofluid analysis. Anal. Chem., 2009, 81(8), 2969-75.
13. Goodwin, R. J.; Pennington, S. R.; Pitt, A. R. Protein and peptides in pictures: imaging with MALDI mass spectrometry. Proteomics, 2008, 8(18), 3785-800.
14. McCarron, J. A.; Zoghbi, S. S.; Shetty, H. U.; Vermeulen, E. S.; Wikstrom, H. V.; Ichise, M.; Yasuno, F.; Halldin, C.; Innis, R. B.; Pike, V. W. Synthesis and initial evaluation of [11C](R)-RWAY in monkey-a new, simply labeled antagonist radioligand for imaging brain 5-HT1A receptors with PET. Eur. J. Nucl. Med. Mol. Imaging, 2007, 34, (10), 1670-82.
15. Nelson, D. R., Cytochrome P450 and the individuality of species. Arch. Biochem. Biophys., 1999, 369(1), 1-10.
16. Lahoz, A.; Donato, M. T.; Castell, J. V.; Gomez-Lechon, M. J. Strategies to in vitro assessment of major human CYP enzyme activities by using liquid chromatography tandem mass spectrometry. Curr. Drug Metab, 2008, 9(1), 12-9.
17. Lahoz, A.; Donato, M. T.; Montero, S.; Castell, J. V.; Gomez-Lechon, M. J. A new in vitro approach for the simultaneous determination of phase I and phase II enzymatic activities of human he-patocyte preparations. Rapid Commun. Mass Spectrom., 2008, 22(2), 240-4.
18. Matusch, A.; Meyer, P. T.; Bier, D.; Holschbach, M. H.; Woitalla, D.; Elmenhorst, D.; Winz, O. H.; Zilles, K.; Bauer, A. Metabolism of the A1 adenosine receptor PET ligand [18F]CPFPX by CYP1A2: implications for bolus/infusion PET studies. Nucl. Med. Biol., 2006, 33(7), 891-8.
19. Ravasi, L.; Kiesewetter, D. O.; Shimoji, K.; Lucignani, G.; Eckelman, W. C. Why does the agonist [(18)F]FP-TZTP bind preferentially to the M(2) muscarinic receptor? Eur. J. Nucl. Med. Mol. Imaging, 2006, 33(3), 292-300.
20. Shimoji, K.; Esaki, T.; Itoh, Y.; Ravasi, L.; Cook, M.; Jehle, J.; Jagoda, E. M.; Kiesewetter, D. O.; Schmidt, K.; Sokoloff, L.; Eckelman, W. C. Inhibition of [18F]FP-TZTP binding by loading doses of muscarinic agonists P-TZTP or FP-TZTP in vivo is not due to agonist-induced reduction in cerebral blood flow. Synapse, 2003, 50(2), 151-63.
21. Jagoda, E. M.; Kiesewetter, D. O.; Shimoji, K.; Ravasi, L.; Yamada, M.; Gomeza, J.; Wess, J.; Eckelman, W. C. Regional brain uptake of the muscarinic ligand, [18F]FP-TZTP, is greatly decreased in M2 receptor knockout mice but not in M1, M3 and M4 receptor knockout mice. Neuropharmacology, 2003, 44(5), 653-61.
22. Kiesewetter, D. O.; Vuong, B. K.; Channing, M. A. The automated radiosynthesis of [18F]FP-TZTP. Nucl. Med. Biol., 2003, 30(1), 73-7.
23. Carson, R. E.; Kiesewetter, D. O.; Jagoda, E.; Der, M. G.; Herscovitch, P.; Eckelman, W. C. Muscarinic cholinergic receptor measurements with [18F]FP-TZTP: control and competition studies. J. Cereb. Blood Flow Metab., 1998, 18(10), 1130-42.
24. Ma, Y.; Kiesewetter, D. O.; Jagoda, E. M.; Huang, B. X.; Eckelman, W. C. Identification of metabolites of fluorine-18-labeled M2 muscarinic receptor agonist, 3-(3-[(3-fluoropropyl)thio]-1,2,5-thiadiazol-4-yl)-1,2,5,6-tetrahydro- 1-me thylpyridine, produced by human and rat hepatocytes. J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci., 2002, 766(2), 319-29.
25. Ma, Y.; Kiesewetter, D. O.; Lang, L.; Der, M.; Huang, B.; Carson, R. E.; Eckelman, W. C., Determination of [18F]FCWAY, [18F]FPTZTP, and their metabolites in plasma using rapid and efficient liquid-liquid and solid phase extractions. Nucl. Med. Biol., 2003, 30 (3), 233-40.
26. Kiesewetter, D. O.; Jagoda, E. M.; Shimoji, K.; Ma, Y.; Eckelman, W. C. Evaluation of [18F]fluoroxanomeline {5-{4-[(6-[18F]-fluorohexyl)oxy]-1,2,5- thiadiazol-3-yl}-1-methyl-1,2,3,6-te trahydropyridine} in muscarinic knockout mice. Nucl. Med. Biol., 2007, 34(2), 141-52.
27. Murphy, A. T.; Bonate, P. L.; Kasper, S. C.; Gillespie, T. A.; De-Long, A. F., Determination of xanomeline in human plasma by ionspray tandem mass spectrometry. Biol. Mass Spectrom., 1994, 23(10), 621-5.
28. Murphy, A. T.; Kasper, S. C.; Gillespie, T. A.; Delong, A. F. Determination of xanomeline and active metabolite, N-desmethylxanomeline, in human plasma by liquid chromatographyatmospheric pressure chemical ionization mass spectrometry. J. Chromatogr. B. Biomed. Appl., 1995, 668(2), 273-80.
29. Cliffe, I. A. A retrospect on the discovery of WAY-100635 and the prospect for improved 5-HT(1A) receptor PET radioligands. Nucl. Med. Biol., 2000, 27(5), 441-7.
30. Pike VW, M. J., Hume SP, Ashworth S, Opacka-Juffry J,; S, O. Pre-clinical development of a radioligand for studies of central 5-HT1A receptors in vivo-[11C]WAY-100635. Med. Chem. Res., 1994, 5, 207-227.
31. Osman, S.; Lundkvist, C.; Pike, V. W.; Halldin, C.; McCarron, J. A.; Swahn, C. G.; Farde, L.; Ginovart, N.; Luthra, S. K.; Gunn, R. N.; Bench, C. J.; Sargent, P. A.; Grasby, P. M. Characterisation of the appearance of radioactive metabolites in monkey and human plasma from the 5-HT1A receptor radioligand, [carbonyl-11C]WAY-100635 - explanation of high signal contrast in PET and an aid to biomathematical modelling. Nucl. Med. Biol., 1998, 25(3), 215-23.
32. Osman, S.; Lundkvist, C.; Pike, V. W.; Halldin, C.; McCarron, J. A.; Swahn, C. G.; Ginovart, N.; Luthra, S. K.; Bench, C. J.; Grasby, P. M.; Wikstrom, H.; Barf, T.; Cliffe, I. A.; Fletcher, A.; Farde, L. Characterization of the radioactive metabolites of the 5-HT1A receptor radioligand, [O-methyl-11C]WAY-100635, in monkey and human plasma by HPLC: comparison of the behaviour of an identified radioactive metabolite with parent radioligand in monkey using PET. Nucl. Med. Biol., 1996, 23(5), 627-34.
33. Gallezot, J. D.; Nabulsi, N.; Neumeister, A.; Planeta-Wilson, B.; Williams, W. A.; Singhal, T.; Kim, S.; Maguire, R. P.; McCarthy, T.; Frost, J. J.; Huang, Y.; Ding, Y. S.; Carson, R. E., Kinetic modeling of the serotonin 5-HT(1B) receptor radioligand [(11)C]P943 in humans. J. Cereb. Blood Flow Metab., 30(1), 196-210.
34. Zhang, X. Y.; Yasuno, F.; Zoghbi, S. S.; Liow, J. S.; Hong, J.; McCarron, J. A.; Pike, V. W.; Innis, R. B. Quantification of serotonin 5-HT1A receptors in humans with [11C](R)-(-)-RWAY: radiometabolite(s) likely confound brain measurements. Synapse, 2007, 61 (7), 469-77.
35. Liow, J. S.; Lu, S.; McCarron, J. A.; Hong, J.; Musachio, J. L.; Pike, V. W.; Innis, R. B.; Zoghbi, S. S. Effect of a P-glycoprotein inhibitor, Cyclosporin A, on the disposition in rodent brain and blood of the 5-HT1A receptor radioligand, [11C](R)-(-)-RWAY. Synapse, 2007, 61(2), 96-105.
36. Yasuno, F.; Zoghbi, S. S.; McCarron, J. A.; Hong, J.; Ichise, M.; Brown, A. K.; Gladding, R. L.; Bacher, J. D.; Pike, V. W.; Innis, R. B. Quantification of serotonin 5-HT1A receptors in monkey brain with [11C](R)-(-)-RWAY. Synapse, 2006, 60(7), 510-20.
37. Carson, R. E.; Wu, Y.; Lang, L.; Ma, Y.; Der, M. G.; Herscovitch, P.; Eckelman, W. C. Brain uptake of the acid metabolites of F-18-labeled WAY 100635 analogs. J. Cereb. Blood Flow Metab., 2003, 23(2), 249-60.
38. Carson, R. E.; Lang, L.; Watabe, H.; Der, M. G.; Adams, H. R.; Jagoda, E.; Herscovitch, P.; Eckelman, W. C. PET evaluation of [(18)F]FCWAY, an analog of the 5-HT(1A) receptor antagonist, WAY-100635. Nucl. Med. Biol., 2000, 27(5), 493-7.
39. Ma, Y.; Lang, L.; Kiesewetter, D. O.; Jagoda, E.; Sassaman, M. B.; Der, M.; Eckelman, W. C. Liquid chromatography-tandem mass spectrometry identification of metabolites of two 5-HT1A antagonists, N-[2-[4-(2- methoxylphenyl)piperazino]ethyl]-N-(2-pyridyl) trans- and cis-4- fluorocyclohexanecarboxamide, produced by human and rat hepatocytes. J. Chromatogr. B. Biomed. Sci. Appl., 2001, 755(1-2), 47-56.
40. Bonne, O.; Bain, E.; Neumeister, A.; Nugent, A. C.; Vythilingam, M.; Carson, R. E.; Luckenbaugh, D. A.; Eckelman, W.; Herscovitch, P.; Drevets, W. C.; Charney, D. S. No change in serotonin type 1A receptor binding in patients with posttraumatic stress disorder. Am. J. Psychiatry, 2005, 162(2), 383-5.
41. Ma, Y.; Lang, L.; Kiesewetter, D. O.; Eckelman, W. C. Liquid chromatography-tandem mass spectrometry identification of metabolites of three phenylcarboxyl derivatives of the 5-HT(1A) antagonist, N-(2-(4-(2-methoxyphenyl) -1-piperazinyl)ethyl)-N-(2-pyridyl) trans-4-fluorocyclohexanecarboxamide (FCWAY), produced by human and rat hepatocytes. J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci., 2002, 780(1), 99-110.
42. Horwitz, S. B. Mechanism of action of taxol. Trends Pharmacol. Sci., 1992, 13(4), 134-6.
43. Kurdziel, K. A.; Kiesewetter, D. O.; Carson, R. E.; Eckelman, W. C.; Herscovitch, P. Biodistribution, radiation dose estimates, and in vivo Pgp modulation studies of 18F-paclitaxel in nonhuman primates. J. Nucl. Med., 2003, 44(8), 1330-9.
44. Kiesewetter, D. O.; Jagoda, E. M.; Kao, C. H.; Ma, Y.; Ravasi, L.; Shimoji, K.; Szajek, L. P.; Eckelman, W. C. Fluoro-, bromo-, and iodopaclitaxel derivatives: synthesis and biological evaluation. Nucl. Med. Biol., 2003, 30(1), 11-24.
45. Boswell, C. A.; McQuade, P.; Weisman, G. R.; Wong, E. H.; Anderson, C. J. Optimization of labeling and metabolite analysis of copper-64-labeled azamacrocyclic chelators by radio-LC-MS. Nucl. Med. Biol., 2005, 32(1), 29-38.
46. Verduyckt, T.; Kieffer, D.; Huyghe, D.; Cleynhens, B.; Verbeke, K.; Verbruggen, A.; Bormans, G. Identity confirmation of 99mTc-MAG3, 99mTc-sestamibi and 99mTc-ECD using radio-LC-MS. J. Pharm. Biomed. Anal., 2003, 32(4-5), 669-78.
47. Liu, S.; Ziegler, M. C.; Edwards, D. S. Radio-LC-MS for the characterization of 99mTc-labeled bioconjugates. Bioconjug. Chem., 2000, 11(1), 113-7.
48. Vanderghinste, D.; Van Eeckhoudt, M.; Terwinghe, C.; Mortelmans, L.; Bormans, G. M.; Verbruggen, A. M.; Vanbilloen, H. P. An efficient HPLC method for the analysis of isomeric purity of technetium-99m-exametazime and identity confirmation using LCMS. J. Pharm. Biomed. Anal., 2003, 32(4-5), 679-85.
49. Ma, Y.; Lang, L.; Reyes, L.; Tokugawa, J.; Jagoda, E. M.; Kiesewetter, D. O. Application of highly sensitive UPLC-MS to determine biodistribution at tracer doses: validation with the 5-HT1A ligand [(18)F]FPWAY. Nucl. Med. Biol., 2009, 36(4), 389-93.
50. Chernet, E.; Martin, L. J.; Li, D.; Need, A. B.; Barth, V. N.; Rash, K. S.; Phebus, L. A. Use of LC/MS to assess brain tracer distribution in preclinical, in vivo receptor occupancy studies: dopamine D2, serotonin 2A and NK-1 receptors as examples. Life Sci., 2005, 78(4), 340-6.
51. Barth, V. N.; Chernet, E.; Martin, L. J.; Need, A. B.; Rash, K. S.; Morin, M.; Phebus, L. A. Comparison of rat dopamine D2 receptor occupancy for a series of antipsychotic drugs measured using radiolabeled or nonlabeled raclopride tracer. Life Sci., 2006, 78(26), 3007-12.